Evaluating the Clinical Efficacy of Zoledronic Acid in the Prevention and Treatment of Osteoporosis in Postmenopausal Women, Compared with Conventional Medications

Document Type : Review Article

Authors

1 MSc Student, Department of Health Economics, School of Health, Tehran University of Medical Sciences, Tehran, Iran

2 Associate Professor, Department of Health Management and Economics, School of Health, Tehran University of Medical Sciences, Tehran, Iran

3 Assistant Professor, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran

4 Associate Professor, Metabolic Research Center, Department of Rheumatology, Qazvin University of Medical Sciences, Qazvin, Iran

5 - Assistant Professor, Department of Health Management and Economics, School of Health, Tehran University of Medical Sciences, Tehran, Iran

6 - PhD Student, Department of Health Economics, School of Health, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Due to the development of drugs, regarding this matter that customers of health services are unable to assess the clinical and financial aspects of medical technologies, evaluating the clinical efficacy of drugs is very important. This study aimed to evaluate the clinical efficacy of zoledronic acid in the prevention and treatment of postmenopausal osteoporosis.Methods: In this systematic review, the Cochrane, PubMed and Google scholar databases were searched using the keywords: “bone mineral density, male osteoporosis, zoledronic acid postmenopausal women osteoporosis”. Inclusion criteria were all menopausal women at risk of or suffering from osteoporosis that used zoledronic acid, at least once, for the prevention or treatment of osteoporosis. Desired outcomes included reduced bone fractures, bone resorption and bone turnover markers, increased bone density, and significant improvement in health-related quality of life in patients with a fracture. The included studies were randomized clinical trials in English language.Findings: Using zoledronic acid significantly increased bone marrow density (BMD) at the total hip, lumbar spine, femoral neck, hip trochanter, and the distal radius; it reduced the incidence of hip fractures, morphometric vertebral fractures, vertebral fractures, any clinical fracture, clinical vertebral fractures, and risk of non-vertebral fracture; also, decreased bone turnover markers in the intervention group compared with the controls.Conclusion: According to safety and clinical effectiveness of zoledronic acid, using this medication in the prevention and treatment of osteoporosis in postmenopausal women is recommended.

Keywords

References

  1. Griggs A, Loscalzo C. Musculoskeletal and connective tissue diseas. Trans. Raissi Dehkordi M, Ghaziany M, Khavaran K. 2nd ed. Tehran, Iran: Taimourzade Publication; 2006. p.1034. [In Persian].
  2. Gharibdoost F. Osteoporosis. 1st ed. Tehran, Iran: Andishmand Publication; 2002. p.9. [In Persian].
  3. Adinepour A, Tohidi M, Dabbaghmanesh MH, Jafari P, Fattahi MR, Ranjbar Omrani GhH. Prevalence of osteoporosis in rural men of Fars based on both local and WHO reference data. Iran J Endocrinol Metab 2010; 12(4): 393-400. [In Persian].
  4. Ebrahimi-Mameghani M, Mahdavi Roshan M, Ebrahimi A. Effect of zinc supplementation on bone mineral density in osteoporotic postmenopausal women: a double blind RCT. Med J Tabriz Univ Med Sci 2009; 31(4): 7-11. [In Persian].
  5. Bagheri P, Haghdoost AA, Dortaj Rabari E, Halimi L, Vafaei Z, Farhangnya M. Ultra analysis of prevalence of osteoporosis in Iranian women "a systematic review and meta-analysis". Iran J Endocrinol Metab 2011; 13(3): 315-25.
  6. Abolhassani F, Mohammadi M, Soltani A. Burden of osteoporosis in Iran. Iran J Public Health 2004; (Suppl): 18-28.
  7. Iranian Rheumatology Association. Osteoporosis [Online]. [cited 2014]; Available from: URL:
  8. http://www.iranianra.ir/files/site1/pages/op.pdf
  9. Keating GM, Scott LJ. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs 2007; 67(5): 793-804.
  10. Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011; 26(3): 503-11.
  11. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009; 114(5): 999-1007.
  12. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346(9): 653-61.
  13. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009; 94(2): 538-44.
  14. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007; 41(1): 122-8.
  15. Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int 2010; 21(7): 1277-85.
  16. Boonen S, Black DM, Colon-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010; 58(2): 292-9.
  17. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 2009; 94(9): 3215-25.
  18. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009; 24(9): 1544-51.
  19. Sambrook PN, Silverman SL, Cauley JA, Recknor C, Olson M, Su G, et al. Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. Bone 2011; 48(6): 1298-304.
  20. Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, et al. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled Horizon Pivotal Fracture Trial. J Bone Miner Res 2011; 26(5): 984-92.
Journal of Isfahan Medical School
Volume 32, Issue 312 - Serial Number 312
November and December 2015
Pages 2104-2123

Files

History

  • Receive Date: 03 October 2013
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics